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A Prospective, Multicentre Study on the Use of Epidermal Graft to 
Optimise Outpatient Wound Management 
 
Abstract 
 
INTRODUCTION 
Current wound management with the use of split thickness skin graft often requires hospital 
admission, a period of immobility, attentive donor site wound care and pain management. 
This study evaluates the feasibility of using a novel epidermal graft harvesting device 
(CelluTome) which allows pain-free epidermal skin grafting in the outpatient clinic setting. A 
prospective series of 35 patients was performed in 2 centres, involving 10 acute and 25 
chronic wounds. All patients were subjected to epidermal grafting in the outpatient specialist 
clinic, without the use of anaesthesia, and allowed to return home after the procedure. 
Completely healed wounds were noted in 22 patients (62.9%). The overall mean time for 50% 
and 100% reduction in wound size was 3.31±2.33 weeks and 5.91±3.48 weeks respectively. 
There was no significant difference in healing times between the acute and chronic wounds 
(50% reduction in wound size; acute 2.20±0.91 weeks versus chronic 3.73±2.63 weeks, 
p=0.171. 100% reduction in wound size; acute 4.80±1.61 weeks versus chronic 6.83±4.47 
weeks, p=0.183). The mean time for donor site healing was 5.49±1.48 days. The mean pain 
score during graft harvest was 1.42±0.95 and the donor site Vancouver Scar Scale was 0 for 
all cases at 6 weeks. This automated device offers autologous skin harvesting in the outpatient 
setting with minimal or no pain and a scar free donor site, equally benefiting both the acute 
and chronic wounds. It has the potential to save NHS resources by eliminating the need for 
theatre space and a hospital bed, while at the same time benefiting patient care.  
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Introduction 
 
The cost of wound management to the NHS is considerable, estimated at about £2.3-3.1 
billion per year1. Chronic wounds can present significant challenges to the practitioner with 
a long healing time and multiple dressing changes. Most of these wounds are managed in 
the outpatient setting with protocols that vary according to geography, institution and 
speciality. Wound coverage by dressings or the use of split thickness skin grafts aims to 
achieve complete healing in the shortest time period with minimal patient morbidity. 
Current wound management with the use of split thickness skin grafts (SSGs) often requires 
hospital admission, even as a day case, anaesthesia, and a period of immobility for some 
patients. The donor site becomes a second, often painful wound, which may take more time 
to heal than the graft site2, 3.  Newer alternatives to SSG such as tissue-engineered skin grafts 
carry their own challenges; namely the cost, lack of availability, and are often limited to 
specialised facilities. 
Epidermal grafting (EG) was first described in 1964 by two Dermatologists, Kiistala and 
Mustakallio4. Their technique proposed the use of negative pressure (150 – 200mmHg), with 
minimal intra-procedure trauma.  However, it was not until 1971, when Falabella5 showed 
that EG was a valuable tool for providing coverage of granulating areas and repigmentation 
of achromic wounds. Although it has been described as cumbersome and time consuming 
there are reports of successful wound healing with the use of epidermal grafting, however, 
to-date it has been minimally explored.  This study evaluates the feasibility of using a novel 
epidermal graft harvesting device, CelluTome, which allows epidermal skin grafting to be 
performed in the outpatient clinic setting, with minimal or no pain, as an alternative to the 
current wound management methodology. 
Methods 
 
A prospective case series was conducted, from July 2014 to March 2015, at two regional 
plastic surgery units in the United Kingdom: the Royal Free Hospital, London and the 
University Hospital of Wales, Cardiff. Epidermal Grafting was an established technique in the 
Trust so a Divisional protocol was developed with trust approval for a new device and all 
patients registered for a prospective audit. 
 
Patient Selection 
Adult patients who had been referred to the department of plastic surgery for consideration 
for SSG due to difficult or non-healing wounds were considered. The wounds were between 
2cm x 2cm and 12cm x 12cm, and had clean and granulating wound beds. Prior to grafting, 
the wound bed was prepared as per standard clinical practice, either with negative pressure 
wound therapy or appropriate dressings, until healthy granulation tissue was present. Wound 
swabs were performed to exclude infection. Details on patient’s demographics, co-
morbidities, wound aetiology, wound type, wound location, wound size, healing time, pain 
scores during graft harvest, wound measurements at each visit, and donor site scar quality 
were recorded. The wound type was classified into acute (<3 months in duration) and chronic 
(≥3 months in duration). This study was conducted in the outpatient setting and patients were 
allowed to return home on the same day after the intervention.  
Epidermal graft harvest and post grafting wound care 
Epidermal grafts were harvested using an automated harvesting system, CelluTome (Acelity)6. 
This device harvests epidermal micrografts, without the use of anaesthesia, via the formation 
of suction blisters, carried out in the outpatient setting. By combining negative pressure (400 
– 500 mmHg) and heat (40oC), this device produces an array of epidermal blisters within 30 
to 50 minutes, providing autologous keratinocytes for grafting (Figure 1). The microdomes are 
formed at the layer of the lamina lucida of the dermo-epidermal junction6. Following the 
harvest, the epidermal grafts are transferred onto a non-adherent silicone dressing (Adaptic 
Touch, Systagenix) and applied onto the wound (Figure 1). The graft is then secured with a 
secondary dressing, while the donor site is dressed with an occlusive dressing (Tegaderm Film, 
3M) (Figure 2). Patients were allowed to return home on the same day after the procedure 
and were reviewed on day 7±3 post-grafting. The patients were reviewed weekly for a 
minimum of 6 weeks or until the wound had healed. 
During the post-operative review the donor site dressing was removed at week 1 and no 
further dressing was required.  The recipient wound was reviewed by the same clinician for 
every case to ensure continuity of care and practice as well as reliability in outcome measure 
assessment. Once the dressing was removed the bed was not tampered with, to allow for the 
fragile keratinocyte layers to set, and a new dressing was applied usually in the form of a non-
adherent silicone dressing, Adaptic Touch (Systagenix), followed by a secondary dressing 
which usually included iNadine (Systagenix) or Aquacel (Figure 2) to deal with the exudate 
levels.  In cases where the exudate level was moderate or high the secondary dressing was 
changed twice weekly. 
 
Outcome measures 
The wounds were measured (length (cm) x width (cm)) and photographed before and after 
grafting, and at each wound review.  The primary outcomes measured were the time taken 
for 50% and 100% reduction in wound size as well as the time taken for the donor site to heal.  
The secondary outcomes measured were pain score during graft harvest and donor site scar 
quality. The pain score was measured using a Numerical Rating Scale, with 0 being no pain 
and 10 being worst pain. The donor site scar quality was evaluated by using the Vancouver 
Scar Scale (VSS) at 6 weeks post grafting7. The VSS assesses 4 variables: vascularity, 
height/thickness, pliability, and pigmentation. Each variable include ranked subscales that are 
summed to obtain a total score ranging from 0 to 13, with 0 representing normal skin and 13 
representing maximum alterations of the skin.  
 
Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics 21 software. The p values of <0.05 
were considered statistically significant. ata was presented as the mean ± standard deviation. 
The time for reduction in wound size between the acute and chronic wounds, and the size 
and type of wound were compared using the independent t-test. The Pearson correlation co-
efficient was used to determine the association between the age and the time for the donor 
site to heal. 
 
 
 
 
 
 
 
 
Results 
 
A total of 35 patients were treated with the epidermal grafting with an average age of 66.1 
years (range: 18-93 years).  Of these patients, 16 were male (45.7%) and 19 were female 
(54.3%) (Table 1). The most common aetiology in this patient cohort was wound dehiscence 
(n=12). There were 10 acute wounds (mean duration: 1.50 ± 0.81 months) and 25 chronic 
wounds (mean duration: 26.3 ± 24.3 months) with the average wound duration of 19.4 
months (range: 0.5-77 months) (Table 2). The majority of the wounds treated were on the leg 
(40.0%), followed by the ankle (17.1%) and abdomen (14.3%). The average wound size was 
20.5 ± 22.4 cm2. There was no difference between the wound size and type of wound (acute: 
11.9 ± 6.65 cm2 versus chronic: 23.9 ± 25.9 cm2, p=0.079). 
Complete wound healing (100% reduction in wound size) was achieved in 22 patients, 62.9%. 
Of these 22 patients, 17 patients (77.3%) healed within 6 weeks, 4 patients (18.2%) within 8 
weeks, and the remaining person healed within 20 weeks.  
The mean time for 50% and 100% reduction in wound size were 3.31± 2.33 weeks and 5.91 ± 
3.48 weeks respectively. There was no significant difference in healing times between the 
acute wounds and the chronic wounds (50% reduction in wound size; acute 2.20 ± 0.91 weeks 
versus chronic 3.73 ± 2.63 weeks, p=0.171. Hundred percent reduction in wound size; acute 
4.80 ± 1.61 weeks versus chronic 6.83 ± 4.47 weeks, p=0.183). 
The mean time for the donor site to heal was 5.49 ± 1.48 days. There was no correlation 
between patient’s age and donor site healing time (Pearson correlation, p=0.915). The mean 
pain score during graft harvest was 1.42 ± 0.95 and the donor site Vancouver Scar Scale was 
0 for all cases at 6 weeks, whereby all donor sites looked similar to the surrounding skin.  
There were seven graft failures due to infection. No improvement in wound size was seen in 
two other patients with chronic wounds, however the wound bed was noted to be more 
active with granulation tissue. No other complications were experienced by the patients. 
 
 
 
 
Case examples 
Case 1: Patient 2/HB.  
A healthy young male sustained a traumatic wound over the left patellar region from a 
motorbike injury. The wound measured 4.5cm x 3.0cm with exposed infra-patellar tendon, 
requiring surgical debridement followed by four weeks of negative pressure wound therapy 
(NPWT). The wound granulated well with the NPWT and subsequently underwent epidermal 
grafting (Figure 3). Complete re-epithelialisation of the wound was noted at 5 weeks post-
grafting while the donor site healed within the first week without any noticeable scar at week 
6.  
Case 2: Patient 7/JZ.  
An 83 year old fit and independent gentleman with history of appendicectomy and right 
hemicolectomy complicated by an incisional hernia in 2011, referred with chronic non-healing 
wound over the central abdomen. The wound measured 4.5cm x 3.5cm and was dressed with 
honey dressings, Inadine (Systagenix) and Silflex (Advancis Medical) prior to epidermal 
grafting (Figure 4). 50% reduction in wound size was achieved at week 4, and complete wound 
healing was achieved at week 8. 
Case 3: Patient 8/GM 
A 60 year old female presented with a four week history of numerous Type 1 pre-tibial 
lacerations secondary to a ladder falling on her right leg (Figure 5). The wound had been 
initially managed with honey dressings, Inadine (Systagenix) and Silflex (Advancis Medical) 
prior to arrival in our clinic. At presentation the wound consisted of four small concave 
granulating wounds all measuring approximately 0.5 x 0.5 cm. There was no growth on 
microbiology swabs from any of the wounds. The patient had myasthenia gravis for which she 
was taking oral prednisolone. Epidermal grafts were taken from the right thigh using the 
CelluTome device and grafted onto the wounds. Adaptic touch (Systagenix) dressings were 
applied. At two weeks the wounds had reduced in size by 50% and at six weeks post-grafting 
all wounds had healed 100%. The donor site healed within five days of harvest. 
 
 
 
Case 4: Patient 12/AL 
A 26 year old female presented with a two week history of an acute thermal burn injury to 
her right leg. The wound measured 9.5 x 2 cm, was granulating and had no growth on 
microbiology swabs. The patient was a smoker but had no other comorbidities. Epidermal 
skin grafts were taken from the right thigh using the CelluTome device and grafted onto the 
wound. Adaptic touch (Systagenix) dressings were applied. Within one week the wound had 
reduced in size by 50% (Figure 6) and within three weeks the wound had healed 100%. The 
donor site healed within seven days of harvest. 
Case 5: Patient 31/JS 
An 88 year old male presented with a two week history of a right forearm laceration following 
trauma. The wound measured 2 x 3.5cm, was granulating and had no growth on microbiology 
swabs. The patient had a past medical history of ischaemic heart disease only and was a non-
smoker. Epidermal grafts were taken from the right thigh and applied to the wound. Adaptic 
touch (Systagenix) dressings were applied. Within three weeks the wound had reduced in size 
by 50% and within five weeks the wound was 100% healed (Figure 7). The donor site healed 
within six days after harvest.  
Case 6: Patient 9/RF 
A 78 year old male presented with a three month history of wound dehiscence of the left 
lateral leg following basal cell carcinoma excision. The wound had broken down shortly after 
surgery and required debridement in theatre before presentation to our clinic. The wound 
measured 4.5 x 6 cm, was granulating and had no growth on microbiology swabs. The patient 
had numerous comorbidities including prostate cancer (not on active treatment), 
myelodysplasia, ischaemic heart disease and smoking. Epidermal grafts were taken from the 
left thigh using the CelluTome device and grafted onto the wound. Adaptic touch dressings 
were applied. At two weeks the wound was showing signs of over granulation and lack of 
graft-take (Figure 8). At four weeks the graft was judged to have failed and a wound swab 
confirmed pseudomonas growth. The donor site healed within five days of harvest. 
 
 
Discussion 
The use of epidermal grafts or blister grafts for the treatment of vitiligo and chronic wounds 
has already been widely reported but it’s use limited due to the lack of reproducible and 
efficient harvesting techniques further limiting its potential to be used in the outpatient 
setting8, 9. This study demonstrates the feasibility of using a novel epidermal harvesting device 
to achieve definitive wound coverage in the outpatient setting.  
The CelluTome device produces an array of epidermal microdomes, comprising of epidermis 
down to the basal layer, immediately available for transfer to the recipient site. Epidermal 
grafts are made of multi-layered keratinocytes, in which a variety of other cell types with 
specialised functions are embedded, such as the melanin pigment-producing melanocytes, 
the immune-competent Langerhans cells, and the neuroendocrine Merkel cell; while its basal 
layer contains epidermal stem cells10. During the early stages of wound healing, keratinocytes 
begin to migrate from wound edges within 24 hours to the wound bed where they proliferate 
and form new epithelium11. Migrating keratinocytes synthesise and deposit a variety of 
extracellular matrix components, such as laminin, fibronectin, and type IV collagen12. In 
addition, numerous growth factors are also produced, namely, epidermal growth factor (EGF), 
transforming growth factor alpha (TGF-a), and heparin-binding growth factor (HB-EGF) which 
acts on the epidermis to drive wound closure13. The epidermal grafts hence act more like a 
bioengineered skin, stimulating the endogenous process of wound healing.  
Another key factor to the success of epidermal grafting is the ability for basal cell outgrowth 
from the graft edge and this occurs for up to a 2mm distance(REF).  This is intrinsic to the 
design of the harvester, which consists of 128 micrograft pores set at a 2mm distance apart 
to allow for the grafts to be raised in this manner (Figure 1).  
Wound healing was a key outcome measured and the results demonstrated that 62.9% of the 
wounds fully healed with the use of Cellutome.  50% wound healing was achieved within 
3.31± 2.33 weeks and complete wound closure was achieved within 5.91 ± 3.48 weeks.  Of 
the wounds that healed 54.5% were chronic wounds that were not responding to dressings 
and conservative management, which potentially implies that the epidermal grafts stimulates 
the healing process in quiescent wound. The donor site wound healed within 5.49 ± 1.48 days 
with excellent aesthetic outcome, requiring neither frequent nursing care nor scar 
management. This result is encouraging as a donor site from a split thickness skin graft can 
take up to 21 days to re-epithelialise with current donor site dressing methods14. 
Furthermore, donor site complications such as infection, pain, and hypertrophic scarring can 
be avoided.  Interestingly there was no significant difference in wound healing time between 
the acute and chronic wounds making the CelluTome equally useful in both types of wounds.  
The aetiology of the wound and anatomical site also had no significant impact on the wound 
healing times. Donor site healing was excellent in all patients with all cases scoring 0 on the 
Vancouver Scar at 6 weeks. As for the pain scores, these were reported to be were very low 
for all patients with a mean pain score during graft harvest was 1.42 ± 0.95 making this a very 
tolerable technique.  
As with all new technologies the costs of intervention needs to be assessed. We did not 
formally undertake a cost analysis. However the series included 8 acute wounds (1.38 ± 0.54 
months) and 22 chronic wounds (29.6 ± 25.2 months)a total of 662 months of dressing care 
was performed before the intervention of CelluTome. If these wounds had been dressed 2-3 
time per week, a total of 5296-7944 dressing changes would have been performed. In total 
30 interventions were performed with 400-600 dressing changes in the 8 weeks of care with 
two thirds of patients achieving a dressing free (healed) outcome. The intervention and 
subsequent treatment therefore costing less than 10% of the previous management costs.  
Our experience shows that this harvesting device can be introduced routinely in the 
outpatient setting for both acute and chronic wounds.  Once a patient has been assessed they 
can be invited back to a routine ‘cellutome’ clinic and undergo the epidermal harvest followed 
by routine dressing changes by the delivering clinical team.  Chronic wounds pose a significant 
burden on the NHS, representing at least 5.5% of NHS budget expenditure (15) therefore such 
technologies that can introduce lasting improvements to wound management should be 
welcomed.   
Limitations of the study 
This is an observational study and therefore prone to selection bias. The data reported 
includes all cases performed in a sequential manner and patients were identified from routine 
referrals. Both units experienced a learning curve and this was attributed to three main 
points;  the quality of the wound bed preparation, ensuring absence of wound bed infection 
(responsible for 7 graft failures), the harvest and post-operative wound care..   Following 
some graft failures due to infection, assessing wounds with a pre-operative swab has become 
the standard approach. The fragility of the epidermal grafts and keratinocyte sheets that 
develop in the weeks post-operatively was acknowledged and as such our practice has 
changed whereby the wound bed is not touched during the first 3-4 weeks of dressing 
changes.  Furthermore, better management of exudate levels with various secondary 
dressings was achieved which also improved results.  
The feasibility of treating acute wounds in the outpatient setting reduces the need for 
patients to be admitted for autologous skin grafting. In addition, the prospect of using this 
device in the emergency department for the management of acute wounds could potentially 
reduce the number of hospital visits. The CelluTome is easy to use and well tolerated by 
patients. Elderly patients with multiple co-morbidities would benefit from this technique as it 
does not require anaesthesia and avoids the complications of bed rest, maintaining patient’s 
independence and quality of life.  
Conclusion 
This automated device offers a novel method in autologous skin harvesting resulting in 
minimal or no pain and a scar free donor site in the outpatient setting. Complete wound 
coverage is achieved, while maintaining patient independence. It has the potential to save 
healthcare resources by eliminating the need for theatre space and a hospital bed, while at 
the same time benefiting patient care. 
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Figures 
 
Figure 1: Illustration of the epidermal graft harvesting device 
(A) The epidermal graft harvesting system: (i) the control unit, (ii) the vacuum head, (iii) the 
harvester. (B) Arrow pointing at the microdomes formed in the vacuum head after 50 minutes 
of suction. (C) Graft Harvest. (D) Microdomes transferred on to non-adhesive silicone 
 
Figure 2: Dressings 
(A) Secondary dressing with Aquacel (B) Secondray dressing with iNadine (C) Further occlusive 
dressing to be applied on top of either (A) or (B) 
 
Figure 3: The wound and donor site of Patient 2/HB 
(A) Healthy granulation tissue was seen on the wound bed after 4 weeks of NPWT. The wound 
measures 4.5cm x 3.0cm over the left patella region. (B) More than 50% of the wound was re-
epithelialised at week 3 post grafting. (C) Complete wound healing was seen at week 5. (D) 
Minimal scabs were seen at the donor site (black arrow) at week 3. (E) No visible scar was 
seen at the donor site (black arrow) at week 6. The donor site looks aesthetically similar to 
the surrounding skin. 
 
Figure 4: The wound of Patient 7/JZ 
(A) 4.5cm x 3.5cm superficial, granulating wound over the central abdomen. (B) At week 4, 
50% of the wound was re-epithelialised. (C) The wound was completely healed at week 6. 
 
 Figure 5: The wound of Patient 8/GM 
(A) Multiple 4-week-old small Type 1 pre-tibial lacerations on right leg. (B) At 2 weeks post 
epidermal grafting, the wounds were 50% healed; (C) 100% healing was achieved at 6 weeks 
post grafting.  
 
 
Figure 6: The wound of Patient 12/AL(A)Burn wound measuring 9.5x2cm over the right leg. (B) 
Complete healing was achieved at 3 weeks post grafting. 
Figure 7: The wound of Patient 31/JS 
(A) Right forearm 2x3.5cm laceration wound. (B) At 3 weeks post epidermal grafting the 
wound was 50% healed; (C) at 5 weeks the wound was 100% healed. 
Figure 8: The wound of Patient 9/RF 
(A) 3 month old left lateral leg wound following BCC excision, wound dehiscence and 
debridement measuring 4.5x6 cm. (B) At 2 weeks post grafting, over granulation seen on 
wound bed. (C) Wound bed was noted to be sloughy at 4 weeks, wound swab confirmed 
pseudomonas growth. 
 
 
 
 
 
 
 
 
 
 
  
Tables 
 
Table 1: Clinical data of patients treated with epidermal graft 
No Patient Gender Age Comorbidities Wound 
aetiology 
Location 
of 
wound 
Duration 
of 
wound 
(month) 
Wound 
size 
(cm2) 
Time for 
50% 
reduction 
of wound 
size 
(weeks) 
Time for 
100% 
reduction 
of wound 
size 
(weeks) 
Time 
for 
donor 
site 
healing 
(days) 
Pain 
score 
during 
graft 
harvest 
VSS 
of 
dono
r site 
scar 
1 SB F 24 Nil Pyogenic 
granulom
a 
Foot 4 6 Failed failed 5 1 0 
2 HB M 18 Nil Trauma  Knee 1 13.5 2 5 5 3 0 
3 RK F 85 IHD, CABG, 
HTN, asthma,  
Venous 
ulcer 
Leg 4 6 2 5 7 2 0 
4 BL F 93 Dementia, 
COPD, HTN, CCF 
Trauma Leg 1 14 1 3 5 1 0 
5 JC M 54 Nil Amputati
on stump 
wound 
dehiscen
ce 
Foot 2 28 2 4 5 2 0 
6 LH F 50 SLE (oral 
steroids) 
Venous 
ulcer 
Ankle 5 8 2 5 7 2 0 
7 JZ M 84 R 
hemicolectomy, 
postop fistula 
and hernia 
Abdomin
al wound 
dehiscen
ce 
Abdome
n 
60 15.8 4 8 5 1 0 
8 GM F 62 Bowen’s 
disease, 
myasthenia 
gravis (on oral 
steroids), 
osteoporosis 
Trauma Leg 1.5 12 2 6 5 2 0 
9 RF M 78 Prostate cancer, 
myelodysplasia, 
IHD, PVD, 
multiple 
BCC/SCC 
Wound 
dehiscen
ce  
Leg 3 27 Failed failed 5 1 0 
10 NS F 91 Breast cancer, 
hypertension, 
smoker, CKD3,  
Trauma Leg 3.5 3  2 3 5 3 0 
11 LR F 64 RA, COPD Trauma Ankle 9 40 failed failed 5 0 0 
12 AL F 26 Anaemia 
smoker 
Burn Leg 0.5 19 1 3 7 1 0 
13 DM F 50 Breast ca and 
chemo, prev 
DVT on warfarin 
Dehiscen
ce of LD 
donor 
site 
Back 4 21 4 8 5 3 0 
14 JB F 52 Hypertension, 
gastric banding, 
abdominoplasty
, thigh lift 
Wound 
dehiscen
ce 
Thigh 1 28 4 8 7 2 0 
15 JM F 76 Cerebral palsy, 
hypothyroid, 
osteoporosis 
SSG 
donor 
site 
Thigh 24 18 2 4 5 2 0 
16 OM M 32 Deaf Trauma Foot 2 26 3 6 5 2 0 
17 KI M 82 IHD, CABG, 
HTN, T2DM, RA 
(on pred + 
methotrexate), 
Hypercholester
olaemia, CVA, 
AAA (4.5cm) 
Wound 
dehiscen
ce 
Leg 2 16 3 6 5 1 0 
18 BR M 78 Prev sigmoid ca, 
colostomy, nec 
fas abdomen, 
CVA 
SSG 
donor 
site 
Thigh 36 39 2 5 7 2 0 
19 HJ F 85 RA VLU Ankle 24 11.25  12 20 7  1 0 
20 AL M 86  Arterial 
leg ulcer 
Ankle 60 5.25 4 No change 9  2 0 
21 IA M 65 PVD 
Diabetes 
Diabetic 
foot ulcer 
Ankle 15 0.9 1 8 7 0 0 
22 MW 
4 
applica
tions  
M 70 Bowel cancer  Wound 
dehiscen
ce 
Abdome
n 
42 123.5  8 Multiple 
small areas 
3 1 0 
23 EVD 
2 
applica
tions 
F 80 PVD Mixed 
arterial 
leg ulcer 
Leg 60 15.84 failed failed 7 2 0 
24 EO F 72 RA Trauma Leg 24 4.94 Wound bed 
more active 
Wound bed 
more active 
7 2 0 
25 MM F 77 Diabetes type 1 Wound 
dehiscen
ce 
Abdome
n 
77 45 Failed Failed 5 1 0 
26 TS 
3 
applica
tions 
M 72 Bowel cancer Wound 
dehiscen
ce 
Abdome
n 
72 22 Multiple 
small areas 
Multiple 
small areas 
3  0 0 
27 BH F 80 Nil Wound 
dehiscen
ce 
Abdome
n 
14 21.6 Failed  failed 7 0 0 
28 PN 
2 
applica
tions 
F 66 Systemic 
sclerosis 
VLU Leg  72 67.2  Failed failed 3 0 0 
29 
BG M 72 Nil VLU Leg  18 4.05 6  No change 3 0 0 
30 
JI M 85 Diiabetes Trauma Leg  21 2.1 4 No change 3 0 0 
31 
JS M 88 IHD, CABG, HTN Trauma Forearm 0.5 7 3 5 5 2 0 
32 
SM M 93 IHD, CABG, 
HTN, AF 
SSG 
donor 
site 
Leg 3 9 2 3 5 2 0 
33 
PS M 28 Nil Wound 
dehiscen
ce 
Ankle 5 6 2 4 5 1 0 
34 
LM F 39 GORD Wound 
dehiscen
ce 
Arm 4 18 4 6 7 3 0 
35 
JK F 58 PE/DVT, PCOS, 
asthma 
Trauma Pretibial 5 14 4 5 7 2 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2: Summary of patient demography and wound characteristics 
Characteristics Number of patients (%) 
Mean age (years) 66.1 ± 21.1 
Gender 
  Male 
  Female 
 
16 (45.71%) 
19 (54.3%) 
Wound aetiology 
   Venous ulcer 
   Arterial ulcer 
   Burns 
   Split thickness skin graft donor site 
   Wound dehiscence 
   Trauma 
   Pyogenic Granuloma 
   Diabetic foot ulcer 
 
5 (14.3%) 
2 (5.7%) 
1 (2.9%) 
3 (8.6%) 
12 (34.3%) 
10 (28.6%) 
1 (2.9%) 
1 (2.9%) 
Type of wound 
  Acute 
  Chronic 
 
10 (28.6%) 
25 (71.4%) 
Mean wound duration (months) 19.4 ± 24.0 
Anatomical location 
  Foot 
  Ankle 
  Leg 
  Knee 
  Thigh 
  Abdomen 
  Back 
  Arm 
  Forearm 
 
3 (8.6%) 
6 (17.1%) 
14 (40.0%) 
1 (2.9%) 
3 (8.6%) 
5 (14.3%) 
1 (2.9%) 
1 (2.9%) 
1 (2.9%) 
 
 
